ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0645

Lupus Fibroblasts from Non-lesional Skin Exhibit Exaggerated Responses to Inflammatory Cytokines and Upregulate Pro-fibrotic Collagens in Patients with Scarring Lesions

Suzanne Shoffner-Beck, Lisa Abernathy-Close, Stephanie Lazar, Amy Hurst, Craig Dobry, Deepika Pandian, Rachael Wasikowski, Kelly Arnold, Johann Gudjonsson, Lam Tsoi and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, Bioinformatics, Dermatology, Fibroblasts, Dermal, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Etiology and Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Cutaneous lupus erythematosus (CLE) is a manifestation of systemic lupus erythematosus (SLE) that can cause significant patient distress and disfiguration secondary to scar. Scarring mechanisms remain poorly understood and interventions for preventing or treating scarring are lacking in SLE/CLE. Fibroblasts (FBs) are involved in the regulation of immune responses, inflammation, and scarring, yet the role of inflammatory mediators on FB function in SLE is unclear. Here, we examined the inflammatory phenotype in FBs isolated from non-lesional skin from healthy controls (HC), and SLE patients with and without scarring CLE.

Methods: Non-lesional punch biopsies were obtained from University of Michigan patients with SLE (n=21), divided into patients with scarring skin lesions (n=8) and non-scarring skin lesions (n=13), as well as HCs (n=34). Scarring disease status was determined using the damage score of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI). FBs were isolated from punch biopsies, cultured, and stimulated with IFN-γ, IFN-ɑ, TNF-ɑ, TGF-????, IL-1????, or UV light. RNA sequencing was performed and differentially expressed genes (DEGs) were determined using DESeq2 with log2FC > 0.6 and adjusted p-value < 0.05. Pathway analysis was performed by filtering the genes with the largest effect size (log2FCCLE – log2FCHC) to identify pathways shared across all stimulations and unique to individual stimulations.

Results: HC and SLE FBs exhibited differential gene expression following cytokine treatment, with the largest effect size differences for TGF-????, TNF-ɑ, IFN-γ, and IFN-ɑ stimulation. Cytokine-cytokine receptor signaling pathway genes were upregulated across all conditions, with relatively more upregulation in SLE FBs in comparison to healthy controls. DEGs included CXCL and CCL genes, interleukins, and TNF. (Fig 1)

Pathway analysis of the scarring and non-scarring states revealed DEGs in the IL-10 pathway, especially specific to stimulation with TGF-????, a known fibrotic factor involved in myofibroblast activation. Interestingly, non-scarring patients had greater upregulation of proinflammatory signatures, including CXCL and CCL genes, and interleukins. Collagen trimer pathway genes were also significantly differentially expressed between scarring and non-scarring states. COL17A1 was up-regulated in scarring, especially after inflammatory signals like TGF-????, TNF-ɑ, and IL-1????, while COLQ, COL21A1, and COL4A3 were generally down-regulated in non-scarring. Histologic confirmation of collagen staining identified pro-fibrotic collagen expression in scarring skin lesions, near inflammatory infiltrates. (Fig 2)

Conclusion: Our results show that while exposure to inflammatory cytokines successfully up-regulates inflammatory pathways in both healthy and SLE fibroblasts, the effect is magnified in SLE. Furthermore, while all SLE fibroblasts are associated with elevated inflammation, FBs from patients who scar associated with upregulation of collagen pathways after TGF-β stimulation. Together, these findings provide important insights into the mechanisms of scarring in CLE and potential targets for intervention.

Supporting image 1

Figure 1: A) The effect sizes (log2FC) under indicated cytokine stimulations in healthy (x-axis) and lupus (y-axis) fibroblasts. Diagonal lines represent what would be expected if there is no difference in gene expression between SLE and healthy conditions. B) Bar plots highlighting the differential gene expression for genes in pathways of interest. C) Heatmap illustrating the relatively higher upregulation of cytokine-cytokine receptor pathway genes in lupus compared to healthy controls.

Supporting image 2

Figure 2: A) The effect sizes (log2FC) under indicated cytokine stimulations in non-scarring (x-axis) and scarring (y-axis) lupus fibroblasts. Diagonal lines represent what would be expected if there is no difference in gene expression between scarring and non-scarring conditions. B) Bar plots highlighting the differential gene expression for genes in pathways of interest. C & D) Heatmaps illustrating the relatively higher upregulation of IL_10 pathway genes in non-scarring disease compared to scarring disease and the upregulation of collagen trimer pathway genes in scarring disease compared with non-scarring.


Disclosures: S. Shoffner-Beck, None; L. Abernathy-Close, None; S. Lazar, None; A. Hurst, None; C. Dobry, None; D. Pandian, None; R. Wasikowski, None; K. Arnold, None; J. Gudjonsson, None; L. Tsoi, None; J. Kahlenberg, AstraZeneca, Bristol-Myers Squibb(BMS), Eli Lilly, GlaxoSmithKlein(GSK), Janssen, Merck/MSD, Gilead.

To cite this abstract in AMA style:

Shoffner-Beck S, Abernathy-Close L, Lazar S, Hurst A, Dobry C, Pandian D, Wasikowski R, Arnold K, Gudjonsson J, Tsoi L, Kahlenberg J. Lupus Fibroblasts from Non-lesional Skin Exhibit Exaggerated Responses to Inflammatory Cytokines and Upregulate Pro-fibrotic Collagens in Patients with Scarring Lesions [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/lupus-fibroblasts-from-non-lesional-skin-exhibit-exaggerated-responses-to-inflammatory-cytokines-and-upregulate-pro-fibrotic-collagens-in-patients-with-scarring-lesions/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lupus-fibroblasts-from-non-lesional-skin-exhibit-exaggerated-responses-to-inflammatory-cytokines-and-upregulate-pro-fibrotic-collagens-in-patients-with-scarring-lesions/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology